Understanding the remaining unmet needs in a post ASCT NDMM setting
Dr Martin Tallman speaks to ecancer at BEST OF ASCO® 2018 MIAMI SYMPOSIUM about acute myeloid leukaemia and acute lymphoblastic leukaemia.
He talks about the high mutation rate, and how this effects treatment.
From this he discusses some of the treatment options and survival rates for these.
Understanding the remaining unmet needs in a post ASCT NDMM setting
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
ASCO 2024: Lung cancer highlights
EHA 2024: Multiple myeloma roundup
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Relapsed refractory multiple myeloma